What is Zacks Research’s Estimate for Revvity Q2 Earnings?

Revvity, Inc. (NYSE:RVTY) – Zacks Research decreased their Q2 2025 earnings per share estimates for Revvity in a report released on Monday, May 19th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.15 per share for the quarter, down from their previous estimate of $1.24. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Zacks Research also issued estimates for Revvity’s FY2025 earnings at $4.90 EPS, Q2 2026 earnings at $1.31 EPS and FY2026 earnings at $5.44 EPS.

Several other research analysts also recently issued reports on RVTY. KeyCorp lifted their price target on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Wells Fargo & Company decreased their price target on shares of Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. UBS Group raised Revvity from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $145.00 to $115.00 in a research report on Thursday, May 1st. Barclays cut their price objective on Revvity from $140.00 to $110.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. Finally, Robert W. Baird reduced their price objective on Revvity from $127.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, April 29th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Revvity has a consensus rating of “Moderate Buy” and a consensus target price of $125.64.

Revvity Price Performance

RVTY stock opened at $93.39 on Wednesday. The company has a market capitalization of $11.01 billion, a P/E ratio of 42.26, a PEG ratio of 3.82 and a beta of 1.02. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The business has a 50 day simple moving average of $98.07 and a 200-day simple moving average of $109.95. Revvity has a twelve month low of $88.53 and a twelve month high of $129.50.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.05. The firm had revenue of $664.76 million during the quarter, compared to the consensus estimate of $662.30 million. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the company earned $0.98 EPS.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, July 18th. Revvity’s payout ratio is presently 11.91%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Assetmark Inc. grew its stake in shares of Revvity by 3,700.0% during the fourth quarter. Assetmark Inc. now owns 266 shares of the company’s stock worth $30,000 after buying an additional 259 shares during the last quarter. Optiver Holding B.V. bought a new position in Revvity in the fourth quarter worth approximately $33,000. Quarry LP increased its stake in Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company’s stock valued at $34,000 after purchasing an additional 95 shares in the last quarter. Millstone Evans Group LLC acquired a new stake in shares of Revvity in the 4th quarter worth about $38,000. Finally, Vermillion Wealth Management Inc. purchased a new stake in shares of Revvity in the fourth quarter worth approximately $41,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.